Delisting risk
Outlook Therapeutics (OTLK)
Develops and commercializes ophthalmic bevacizumab for wet age-related macular degeneration.
$0.6273
Pre-market−0.00 (−0.48%)
At close$0.6303(+1.16%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions59 holders · as of Mar 31, 2026 | 8.87% | 10.73M shares | |
| Insiders6 holders · as of Aug 14, 2026 | 0.81% | 974.9K shares | |
| Otherremainder | 90.32% | 109.16M shares |
120.86M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (120.86M in the company's Sep 3, 2026 report, 187.00M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
59 holders · 10.73M shares · 17 new positions · 32 increased · 7 reduced · 18 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.17M | 3.45% | +4.17Mnew | May 15, 2026 |
| Vanguard Capital Management LLC | 1.97M | 1.63% | +1.97Mnew | May 15, 2026 |
| Geode Capital Management, LLC | 603.6K | 0.50% | +287.1K | May 15, 2026 |
| Gilpin Wealth Management, LLC | 600.2K | 0.50% | +246.0K | Apr 21, 2026 |
| BlackRock, Inc. | 477.5K | 0.40% | +72.9K | May 13, 2026 |
| Commonwealth Equity Services, LLC | 470.0K | 0.39% | +357.5K | Apr 27, 2026 |
| Warberg Asset Management LLC | 275.0K | 0.23% | +275.0Knew | May 7, 2026 |
| Renaissance Technologies LLC | 255.2K | 0.21% | +255.2Knew | May 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Sukhtian Ghiath M.incl. GMS Ventures & Investments | 16.40% | 42.63M | 13D | Aug 14, 2026 ↗ |
| CVI Investments, Inc. | 9.90% | 24.71M | 13G | Aug 19, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 14, 2026 | Robert Charles Jahrdirector, officer: Chief Executive Officer | Purchase · 2 lots | 303,030 | $1.05 | 303,030 |
| Aug 12, 2026 | Ghiath M. Sukhtiandirector, 10 percent owner: | Purchase · 2 lots | 5,050,504 | $1.05 | 27,142,572 |
| Aug 14, 2026 | Lawrence A. Kenyondirector, officer: Chief Financial Officer | Purchase · 2 lots | 202,020 | $1.05 | 207,966 |
| Jul 29, 2026 | Faisal Ghiath Sukhtiandirector | Purchase | 95,398 | $1.05 | 220,972 |
| Jun 2, 2026 | Yezan Munther Haddadindirector | Purchase | 29,000 | $0.8326 | 66,167 |
| May 28, 2026 | Ghiath M. Sukhtiandirector, 10 percent owner: | Purchase · 3 lots | 20,569,708 | $0.5855 | 30,663,496 |
| May 26, 2026 | Kurt J. Hilzingerdirector | Purchase | 400,000 | $0.4413 | 423,655 |
| May 26, 2026 | Randy H. Thurmandirector | Purchase | 5,000 | $0.4290 | 5,593 |
| May 26, 2026 | Yezan Munther Haddadindirector | Purchase | 34,000 | $0.4400 | 37,167 |
| May 27, 2026 | Faisal Ghiath Sukhtiandirector | Purchase | 122,174 | $0.4093 | 125,574 |
CongressHouse and Senate disclosures
Not reported.